-
Fosun Kite and Medi Cover Launch First Value-Based Payment Plan for Lymphoma Treatment
•
Fosun Kite and Medi Cover, a health management and patient service platform under Sinopharm (HKG: 1099), have jointly introduced the first value-based payment (VBP) plan for lymphoma associated with Fosun Kite’s chimeric antigen receptor (CAR) T cell therapy, Yescarta (axicabtagene ciloleucel). Under this innovative plan, eligible patients who do not…
-
Fosun Kite’s Yescarta Gains NMPA Approval for Refractory Large B-Cell Lymphoma
•
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196; HKG: 2196) and Gilead (NASDAQ: GILD) subsidiary Kite Pharma, has announced that its product Yescarta (axicabtagene ciloleucel) has obtained marketing approval from the National Medical Products Administration (NMPA) for a new indication…
-
Kite Pharma’s Yescarta Marketing Rights Transferred to Gilead Sciences K.K. in Japan
•
US immunotherapy specialist Kite Pharma, Inc. has announced that the Marketing Authorization for Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, has been transferred from Daiichi Sankyo Co., Ltd. (TYO: 4568) to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc (NASDAQ: GILD). History of Yescarta and…
-
Shanghai Fosun High Technology Partners with NICE for Joint Innovation Centers
•
China-based conglomerate Shanghai Fosun High Technology (Group) Co., Ltd has entered into a partnership with the National Innovation Center par Excellence (NICE), a comprehensive national technology innovation center approved by the Ministry of Science and Technology (MOST). This collaboration aims to strengthen production, education, and research ties between the entities.…
-
Pudong New Area Grants Duty-Free Import Qualifications to Seven Companies
•
Seven companies have been awarded scientific and technological innovation duty-free import qualification designations by the foreign R&D center in Pudong New Area. Among the awardees are Fosun Kite Biotechnology Co., Ltd, a joint venture (JV) between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) and Gilead subsidiary Kite Pharma, as…
